Dr. Marlene Krauss
Throughout her life, Dr. Marlene Krauss has been a pioneer, breaking boundaries, doing her part to advance the women’s movement, and combining medical and investment banking experience to develop medical treatments that have changed our culture.
Dr. Krauss is the CEO and director of KBL Merger Corp. IV, the fourth special purpose acquisition company (SPAC) she has founded. It raised $100 million during its IPO in May 2017 with the goal of acquiring a profitable operating company in the health and wellness space.
Dr. Krauss is managing director of KBL Healthcare Ventures, an entity that has funded and invested in numerous groundbreaking healthcare companies. Her investments include Summit Autonomous Inc., which manufactures the Summit Technology excimer laser, the first laser to be approved by the FDA for LASIK refractive eye surgery.
Dr. Krauss received a B.A. from Cornell University, an M.B.A. from Harvard Business School (she has since received the Alumni Achievement Award and is on the Dean's Committee) and an M.D. from Harvard Medical School. She trained at Beth Israel Hospital and the Deaconess Hospital, both of which are Harvard-affiliated hospitals, as well as at Mt. Sinai Hospital in New York. In 1985, Dr. Krauss completed her training as a vitreoretinal surgeon at New York Hospital, where she has served as Clinical Instructor of Ophthalmology. She is a Board Certified Ophthalmologist.
Dr. Krauss has co-founded and/or led the initial financing for numerous market-leading healthcare companies, including:
- Lumenos, a provider of health plans to self-insured employers. She subsequently sold the company to Wellpoint, the largest health benefits firm in the United States.
- Candela Corporation, a Nasdaq Global Market-listed developer of advanced aesthetic laser systems that allow physicians and personal care practitioners to treat a wide variety of cosmetic and medical conditions.
- Summit Autonomous Inc., formerly a Nasdaq Global Market-listed manufacturer and supplier of excimer laser systems and related products used to perform procedures that correct common refractive vision disorders such as nearsightedness, farsightedness and astigmatism.
- Cambridge Heart Inc., an Over The Counter Bulletin Board listed company that is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease.
Dr. Krauss is a fellow of the American Academy of Ophthalmology and has served as vice chairperson of the business committee of the Metropolitan Museum of Art, and as director of the Harvard Business School Board of Dean’s Advisors. She was the second woman to receive the Harvard Business School’s Alumni Achievement Award.